BioMedReports | TalkMarkets | Page 2
Biotech Investing, Healthcare Stocks
Contributor's Links: BioMedReports
BioMedReports.com was co-founded by M.E. Garza and Mike Havrilla in early 2009. Both were successful traders and investors who had historically made some of their BEST TRADESmore

Articles

Latest Posts
17 to 32 of 77 Posts
PTC Therapeutics, Inc. Commenced A Rolling Submission Of A New Drug Application
Translarna is intended to treat nonsense Duchenne muscular dystrophy.
CERS Reports US Phase 2 Clinical Trial Of INTERCEPT Met Primary Endpoint; VBLT Announces Positive Phase 2a Data For VB-111
CERS announced its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood System. VBLT announced positive results from its exploratory Phase 2a study of VB-11.
Achillion Pharmaceuticals, Inc. Shares Rose High After The Success Of Drug Hep C
After the biotech reported that the NS5A drug of Achillion Pharmaceuticals, Inc. combined with Gilead's Sovaldi scored a quick cure among a small group of hepatitis C patients after only 6 weeks of treatment the shares of Achillion rose high.
Aratana Therapeutics Inc Hits 5-Month High On Positive Development
After the announcement of positive results from the pivotal late-stage field study of its novel drug, AT-001 by Aratana Therapeutics Inc., its stock rose over 26% to $16.50.
Curis Reports Dosing Of First Patient In Phase 1 Trial Of CUDC-907; FUJIFILM Completes Acquisition Of Kalon Biotherapeutics
CRIS, a drug development company announced that the first patient has been treated in a Phase I clinical study of CUDC-907. (FDBU), a FUJIFILM Corporation subsidiary, today announced the completion of its acquisition of Kalon Biotherapeutics LLC.
CARA Announces Positive Top-Line Data From Phase 1b Trial Of IV CR845; PVCT To Sponsor AAPI
CARA a bio-pharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain , PVCT announced it has agreed to sponsor the activities of the American Association of Physicians of Indian Origin.
TPI Expects To Receive GMP By End Of 2014; NVIV Reports FDA Approval To Expedite Enrollment For Pilot Trial
(TPI) Expects to receive GM, (NVIV) announced approval by the U.S. FDA for an expedited enrollment plan for the company’s ongoing pilot trial of its investigational Neuro-Spinal Scaffold.
After Merck-Cubist Merger, Is Tetraphase Pharmaceuticals In In The Pipeline To Be Acquired?
Tetraphase Pharmaceuticals Inc may put itself up for sale.
ChemoCentryx's Lead Drug Meets Phase II Objective; Novartis Reports Results Of Trial Evaluating Use Of Afinitor
Below is a look at some of the headlines for companies that made news in the healthcare sector on December 12, 2014.
APRI Announces First Patient Enrolled In Phase 2a Trial For RayVa; Keryx Announces Issuance Of New U.S. Patent For Auryxia
A look at some of the headlines for companies that made news in the healthcare sector on December 4, 2014, including APRI, KERX, ALDX, CCXI
CYTR Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin; GHDX Predicts Outcomes In Prostate Cancer Patients
CYTR announced that its clinical trials for aldoxorubicin have been placed on partial clinical hold. GHDX announced results from two studies of the Oncotype DX® prostate cancer test.
PRTA Reports Initiation Of NEOD001 Global Phase 3; KERX Offers Phase 2 Trial Results For Auryxia
PRTA announced the initiation of the VITAL Amyloidosis Study. KERX announced the publication of Auryxia phase 2 clinical trial results.
CPHD Receives FDA Clearance For Xpert Flu/RSV XC; SUPN Receives Issuance Of Fifth US Patent
CPHD announced it has received clearance from the U.S. FDA to market its Xpert®, SUPN, announced the issuance of a fifth patent (number 8,889,191) by the United States Patent and Trademark Office (USPTO), its novel once-daily extended-release topiramate product.
OMED Offers Data From Demcizumab; CELG Receives Positive CHMP Opinion For OTEZLA
OMED a clinical-stage company presenting data in two posters, highlighting the company's translational research and biomarker efforts for its tarextumab. CELG announced that the (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA.
AEZS Adds Hollings Cancer Center To Multi-National Phase 3 Trial; MRNA And Mirna Amend License Agreement
AEZS announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina. MRNA announced they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics.
PTCT Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial; OMER Inhibits Thrombus Formation
PTC Therapeutics and Omeros each announce new study phase.
17 to 32 of 77 Posts